26
W
hat are Sanofi activities in
Russia? What is your compa-
ny’s ranking on the Russian
market?
Sanofi is a global diversified biophar-
maceutical company focused on
human health. With more than
100,000 people in 100 countries,
Sanofi is transforming scientific
innovation into healthcare solutions
around the globe.
Sanofi has been in Russia since 1970.
Over 2 000 people are working for
Sanofi in Russia, and our portfolio in
the country now offers health solu-
tions for a very wide range of disea-
ses and conditions: from cough and
cold to diabetes and cardio-vascular
diseases, from addressing headache
to rare diseases, oncology and multi-
ple sclerosis, and many other. Sanofi
has been taking leading positions on
the Russian pharmaceutical market
for the last 6 years.
We continuously invest into the
Russian economy: thus, in 2010 we
opened after a considerable renova-
tion Sanofi-Aventis Vostok production
plant, in the Orel region, where pro-
duction of the modern insulins, and
oncology drugs was established. This
is a strategic project, in which I per-
sonally participated, and I am proud
to say that this production site being
the second largest Sanofi insulin fac-
tories after Frankfurt, has capacities
allowing to fully meet the existing
demand in insulins in Russia and
European countries. Last summer
at the Saint-Petersburg Economic
Forum, we announced launch of the
export of insulins from this plant to
the EU countries, and in October 2017
signed special investment contract
(SPIC) with the Ministry of Trade and
Industry of Russian Federation and
Orel region government.
SPIC is aimed at production moderni-
zation, deepening of localization of
next generation insulin manufacturing
to the stage of the finished dosage
form in 2019, as well as further
development of the export potential
for supplies of modern Orel insulin
abroad. As for manufacturer that
localizes production in Russia, the
SPIC guarantees that the state requi-
rements including tax relief remain
unchanged, as well as secures a local
status for the drug that is produced
within the SPIC before the start of
production of the finished dosage
form.
Besides our own production site, we
are also developing projects with
local partners: localization of the
pediatric five-component combo
vaccine against diphtheria, tetanus,
pertussis, poliomyelitis and Hib-
infection at the Nanolek company
facility, as well as partner projects
on localization of the socially
important drugs with R-Farm and
Pharmstandart companies.
All of this illustrate our long-term
commitment to the country and the
importance of Russia as a market for
Sanofi.
Operating in Russia since 1970, Sanofi is particularly committed to fighting diabetes,
thanks to its local insulin manufacturing plant.
Olivier CHARMEIL,
Executive Vice President & General Manager, General Medicines and Emerging Markets,
Sanofi
©DR
“ Sanofi, a leading position
in the pharmaceutical market ”
©DR
